{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:02:50Z","timestamp":1780722170249,"version":"3.54.1"},"reference-count":177,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is the most complex and aggressive disease with the worst rates of unresectable or metastatic disease at diagnosis, resistance to systemic therapy, and case fatality rate (CFR) among leading cancers. In non-metastatic disease, neoadjuvant treatment with modern chemotherapeutic regimens followed by surgical resection and\/or adjuvant mFOLFIRINOX has significantly improved oncological outcomes. However, recurrence rates remain alarmingly high, while immune checkpoint inhibitors (ICIs) or molecularly targeted therapy have not yet demonstrated clinical benefits. Comprehensive genomic profiling through NGS-based approved assays such as TruSight Oncology 500 (TSO500) could guide targeted therapy. Rapidly evolving mRNA cancer vaccines and circulating tumor DNA (ctDNA)-based prediction of minimal residual disease (MRD) and recurrence risk hold great promise towards the realization of rational combination therapy to improve recurrence-free survival (RFS) and overall survival (OS). More recently, single-cell multiomics (SC MO), spatial proteomics and transcriptomics (SPT), artificial intelligence (AI), and systems biology have revolutionized cancer research, enabling holistic tumor microenvironment (TME) analysis. In this comprehensive review, we describe the latest advances and unmet needs in the standard of care of PDAC. Moreover, we discuss the expectations of ongoing randomized clinical trials of adjuvant mRNA vaccine-based therapy and ctDNA MRD testing as prognostic biomarkers, towards personalized treatment to improve RFS and OS in a medium-term perspective. With a longer perspective, we explore how harnessing SC MO, SPT, AI, and systems biology can reveal the 3D spatial organization of interacting cancer, immune, and stromal cells. Multi-dimensional TME-, TSO500- and ctDNA-based framework of dynamic biomarkers are of paramount importance to achieve an optimal patient-specific perioperative multimodal treatment combining precision immunotherapy, targeted drugs, and modern chemotherapy, translated into future practice-changing clinical trials, that could eliminate MRD towards recurrence prevention.<\/jats:p>","DOI":"10.3390\/cancers18111824","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:45:08Z","timestamp":1780404308000},"page":"1824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Standard of Care to mRNA Cancer Vaccines and Spatial Architecture-Based Precision Therapy in PDAC: Challenges and Expectations"],"prefix":"10.3390","volume":"18","author":[{"given":"Elena X.","family":"Stea","sequence":"first","affiliation":[{"name":"Centre for Biosystems and Genome Medicine, Ioannina University, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kydonakis","sequence":"additional","affiliation":[{"name":"First Department of Surgery, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios H.","family":"Roukos","sequence":"additional","affiliation":[{"name":"Centre for Biosystems and Genome Medicine, Ioannina University, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic Cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","article-title":"Resection of Pancreatic Cancer in Europe and USA: An International Large-Scale Study Highlighting Large Variations","volume":"68","author":"Huang","year":"2019","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.23.01311","article-title":"Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study","volume":"42","author":"Dekker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"e70043","article-title":"Cancer Statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamasurg.2023.7872","article-title":"Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial","volume":"159","author":"Mackay","year":"2024","journal-title":"JAMA Surg."},{"key":"ref_6","unstructured":"Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Pineros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2026, March 27). Global Cancer Observatory Cancer Today. International Agency for Research on Cancer, Lyon. References\u2014Scientific Research Publishing. Available online: https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=2909542."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX versus PAXG for Stage I-III Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (PACT-21 CASSANDRA): Results of the First Randomisation Analysis of a Randomised, Open-Label, 2 \u00d7 2 Factorial Phase 3 Trial","volume":"406","author":"Reni","year":"2026","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2400050","DOI":"10.1200\/OA-24-00050","article-title":"Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment","volume":"1","author":"Finan","year":"2024","journal-title":"JCO Oncol. Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic Cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/ctrv.2000.0164","article-title":"Current Status and Future Perspectives in Gastric Cancer Management","volume":"26","author":"Roukos","year":"2000","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncponc0930","article-title":"Individualized Preventive and Therapeutic Management of Hereditary Breast Ovarian Cancer Syndrome","volume":"4","author":"Roukos","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The Changing Treatment Landscape of EGFR-Mutant Non-Small-Cell Lung Cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMe058196","article-title":"Trastuzumab in the Treatment of Breast Cancer","volume":"353","author":"Hortobagyi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4161\/cbt.6.3.3994","article-title":"Molecular Genetic Tools Shape a Roadmap towards a More Accurate Prognostic Prediction and Personalized Management of Cancer","volume":"6","author":"Roukos","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-009-0766-0","article-title":"Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance","volume":"17","author":"Roukos","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41591-025-04086-8","article-title":"Real-World Clinical Utility of Comprehensive Genomic Profiling in Advanced Solid Tumors","volume":"32","author":"Saito","year":"2026","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/annonc\/mdz236","article-title":"ctDNA to Detect Minimal Residual Disease in Pancreatic Cancer: Moving into Clinical Trials","volume":"30","author":"Montagut","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41571-025-01077-z","article-title":"The Tumour Microenvironment in Pancreatic Cancer\u2014New Clinical Challenges, but More Opportunities","volume":"22","author":"Kung","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S1470-2045(24)00523-0","article-title":"The Current and Future Global Burden of Cancer among Adolescents and Young Adults: A Population-Based Study","volume":"25","author":"Hughes","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00535-021-01806-y","article-title":"A Systematic Review of the Prevalence of Germline Pathogenic Variants in Patients with Pancreatic Cancer","volume":"56","author":"Goldstein","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"Kundra","year":"2023","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41379-021-00902-x","article-title":"Pancreatic Ductal Adenocarcinomas Associated with Intraductal Papillary Mucinous Neoplasms (IPMNs) versus Pseudo-IPMNs: Relative Frequency, Clinicopathologic Characteristics and Differential Diagnosis","volume":"35","author":"Muraki","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217662","DOI":"10.1016\/j.canlet.2025.217662","article-title":"Pancreatic Cancer Precursor Lesions\u2014Can Immunotherapy Prevent Progression into Pancreatic Ductal Adenocarcinoma?","volume":"619","author":"Enzler","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of Oncogenic KRAS in the Diagnosis, Prognosis and Treatment of Pancreatic Cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-Generation DNA Sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_30","unstructured":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020). Pan-Cancer Analysis of Whole Genomes. Nature, 578, 82\u201393."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s43018-023-00526-x","article-title":"Single-Cell Profiling to Explore Pancreatic Cancer Heterogeneity, Plasticity and Response to Therapy","volume":"4","author":"Rad","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and Heritable Factors in the Causation of Cancer\u2014Analyses of Cohorts of Twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/1055-9965.EPI-18-1235","article-title":"Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study","volume":"28","author":"Chen","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","article-title":"Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer","volume":"6","author":"Roberts","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.18.01512","article-title":"Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance","volume":"37","author":"Abe","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","article-title":"Long-Term Yield of Pancreatic Cancer Surveillance in High-Risk Individuals","volume":"71","author":"Overbeek","year":"2022","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Owens, D.K., Davidson, K.W., Krist, A.H., Barry, M.J., Cabana, M., Caughey, A.B., Curry, S.J., Doubeni, C.A., and Epling, J.W. (2019). Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA, 322, 438\u2013444.","DOI":"10.1001\/jama.2019.10232"},{"key":"ref_38","unstructured":"(2026, March 27). Guidelines Detail. NCCN. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1245\/s10434-024-15222-y","article-title":"Long-Term Oncologic Outcome Following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-Analysis","volume":"31","author":"Beger","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100673","DOI":"10.1016\/j.lanepe.2023.100673","article-title":"Minimally Invasive versus Open Distal Pancreatectomy for Resectable Pancreatic Cancer (DIPLOMA): An International Randomised Non-Inferiority Trial","volume":"31","author":"Korrel","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/j.lanepe.2024.100864","article-title":"Robotic versus Open Partial Pancreatoduodenectomy (EUROPA): A Randomised Controlled Stage 2b Trial","volume":"39","author":"Klotz","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant Chemotherapy with Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant Immune Checkpoint Blockade: A Window of Opportunity to Advance Cancer Immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2025.2572980","article-title":"Combination Therapy in Neoadjuvant and Metastatic Settings in Hot Tumors: Strengths and Weaknesses","volume":"26","author":"Stea","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate Surgery Compared with Short-Course Neoadjuvant Gemcitabine plus Capecitabine, FOLFIRINOX, or Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Cancer (ESPAC5): A Four-Arm, Multicentre, Randomised, Phase 2 Trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO-24-01378","article-title":"Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 Study)","volume":"43","author":"Schwarz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus Upfront Surgery for Resectable Pancreatic Head Cancer (NORPACT-1): A Multicentre, Randomised, Phase 2 Trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM\/Nab-PTX) for Borderline-Resectable Pancreatic Cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant Chemotherapy with Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II\/III Prep-02\/JSAP05 Trial","volume":"283","author":"Unno","year":"2026","journal-title":"Ann. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00280-017-3288-7","article-title":"A Phase II Trial of Neoadjuvant Chemoradiotherapy with Intensity-Modulated Radiotherapy Combined with Gemcitabine and S-1 for Borderline-Resectable Pancreatic Cancer with Arterial Involvement","volume":"79","author":"Nagakawa","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jeon, H.J., Jeong, H.J., Lim, S.Y., Yoon, S.J., Kim, H., Han, I.W., Heo, J.S., and Shin, S.H. (2022). Pathological Response Predicts Survival after Pancreatectomy Following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. Cancers, 15.","DOI":"10.3390\/cancers15010294"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.surg.2024.07.026","article-title":"Pathologic Complete Response Following Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma: Impact on Survival and Recurrence","volume":"176","author":"Tamburrino","year":"2024","journal-title":"Surgery"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or Only Adjuvant Gemcitabine plus Nab-Paclitaxel for Resectable Pancreatic Cancer (NEONAX)-a Randomized Phase II Trial of the AIO Pancreatic Cancer Group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological Benefits of Neoadjuvant Chemoradiation with Gemcitabine Versus Upfront Surgery in Patients with Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-Label, Multicenter Phase 2\/3 Trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/SLA.0000000000006269","article-title":"Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer","volume":"282","author":"Cass","year":"2025","journal-title":"Ann. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/SLA.0000000000006004","article-title":"Predicting Long-Term Disease-Free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study","volume":"279","author":"Schouten","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_68","first-page":"573","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"391","author":"Sorscher","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.trecan.2023.04.001","article-title":"Immune Cells in Residual Disease and Recurrence","volume":"9","author":"Ceyhan","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer Drug-Tolerant Persister Cells: From Biological Questions to Clinical Opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/jnci\/91.13.1113","article-title":"Detection and Clinical Importance of Micrometastatic Disease","volume":"91","author":"Pantel","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2159-8290.CD-19-1508","article-title":"The Evolutionary Origins of Recurrent Pancreatic Cancer","volume":"10","author":"Sakamoto","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"103540","DOI":"10.1016\/j.drudis.2023.103540","article-title":"Longitudinal ctDNA Profiling in Precision Oncology and Immun\u03bf-Oncology","volume":"28","author":"Filis","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2011.04.014","article-title":"Minimal Residual Disease in Solid Neoplasia: New Frontier or Red-Herring?","volume":"38","author":"Mordant","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, X., Shen, W., Yao, L., Li, C., You, H., and Guo, D. (2025). Current Status and Future Prospects of Molecular Imaging in Targeting the Tumor Immune Microenvironment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1518555"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e191945","DOI":"10.1172\/JCI191945","article-title":"Experimental Models of Pancreas Cancer: What Has Been the Impact for Precision Medicine?","volume":"135","author":"Pantazopoulou","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semcancer.2024.09.002","article-title":"Unravelling the Complexities of Resistance Mechanism in Pancreatic Cancer: Insights from in Vitro and Ex-Vivo Model Systems","volume":"106\u2013107","author":"Lencioni","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1126\/science.560061","article-title":"Primary Bioassay of Human Tumor Stem Cells","volume":"197","author":"Hamburger","year":"1977","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and Expansion of Human Colon-Cancer-Initiating Cells","volume":"445","author":"Lombardi","year":"2007","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/cdd.2008.20","article-title":"Cancer Stem Cells\u2014Old Concepts, New Insights","volume":"15","author":"Vermeulen","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The Cancer Stem Cell: Premises, Promises and Challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature21713","article-title":"A Distinct Role for Lgr5+ Stem Cells in Primary and Metastatic Colon Cancer","volume":"543","author":"Kurtova","year":"2017","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2020.02.008","article-title":"Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer","volume":"26","author":"Fumagalli","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-21-0933","article-title":"Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage","volume":"82","author":"Heinz","year":"2022","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","article-title":"Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells","volume":"611","author":"Cortina","year":"2022","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer Stem Cells: Advances in Knowledge and Implications for Cancer Therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer Biomarkers: Emerging Trends and Clinical Implications for Personalized Treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013). The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat. Genet., 45, 1113\u20131120.","DOI":"10.1038\/ng.2764"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","article-title":"Tumour and Microenvironment Crosstalk in NSCLC Progression and Response to Therapy","volume":"22","author":"Rahal","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the Analytical Validity of Circulating Tumor DNA Sequencing Assays for Precision Oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"J\u00e1come, A.A., and Johnson, B. (2023). Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?. Cells, 12.","DOI":"10.3390\/cells12071068"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of Cell-Free DNA Analysis to Cancer Treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal Residual Disease Detection Using a Plasma-Only Circulating Tumor DNA Assay in Patients with Colorectal Cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","article-title":"Minimal Residual Disease in Colorectal Cancer. Tumor-Informed versus Tumor-Agnostic Approaches: Unraveling the Optimal Strategy","volume":"36","author":"Camblor","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e16505","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of Tumor-Informed and Tumor-Na\u00efve Sequencing Assays for ctDNA Detection in Breast Cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-024-02683-0","article-title":"Japan Society of Clinical Oncology Position Paper on Appropriate Clinical Use of Molecular Residual Disease (MRD) Testing","volume":"30","author":"Kobayashi","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","article-title":"Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial","volume":"10","author":"Cecchini","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Du, Z., Chen, S., Qin, Y., Lv, Y., Du, X., Yu, H., and Liu, Z. (2025). Efficacy and Safety of Perioperative Immunotherapy for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32030184"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semcancer.2017.03.003","article-title":"The Challenge of Targeting Cancer Stem Cells to Halt Metastasis","volume":"44","author":"Agliano","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.15252\/emmm.201707550","article-title":"A Genome Editing Approach to Study Cancer Stem Cells in Human Tumors","volume":"9","author":"Cortina","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer Stem Cells Revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt Pathways in Cancer Stem Cells: Clinical Update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","article-title":"Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells\u2014A Clinical Update","volume":"17","author":"Clara","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","article-title":"Targeting Notch in Oncology: The Path Forward","volume":"20","author":"Majumder","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-020-00901-6","article-title":"Emerging Agents That Target Signaling Pathways in Cancer Stem Cells","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic Strategies to Target RAS-Mutant Cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D Inhibition Reprograms the Microenvironment of Early and Advanced Pancreatic Cancer to Promote FAS-Mediated Killing by CD8+ T Cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14737159.2025.2544233","article-title":"Molecular Deciphering of Melanoma: Advances and Challenges of Neoadjuvant and Perioperative Treatment","volume":"25","author":"Stea","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Oh","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting Neoantigens to Augment Antitumour Immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e2200706","DOI":"10.1200\/PO.22.00706","article-title":"Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience","volume":"7","author":"Coston","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning Cold Tumors into Hot Tumors to Ignite Immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and Clinical Significance of Tumour-Infiltrating Lymphocytes in the Era of Immunotherapy: A Multidimensional Approach","volume":"22","author":"Sanmamed","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Gaebler, D., Hachey, S.J., and Hughes, C.C.W. (2024). Microphysiological Systems as Models for Immunologically \u2018Cold\u2019 Tumors. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1389012"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent Advances in Therapeutic Cancer Vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T Cell States in Human Cancer: Insights from Single-Cell Analysis","volume":"20","author":"Thommen","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-Cancer Single-Cell Landscape of Tumor-Infiltrating T Cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e003231","DOI":"10.1136\/jitc-2021-003231","article-title":"Immuno-Oncology Trends: Preclinical Models, Biomarkers, and Clinical Development","volume":"10","author":"Franklin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of Unique Neoantigen Qualities in Long-Term Survivors of Pancreatic Cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen Quality Predicts Immunoediting in Survivors of Pancreatic Cancer","volume":"606","author":"Sethna","year":"2022","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"35848","DOI":"10.1038\/srep35848","article-title":"Exploiting the Neoantigen Landscape for Immunotherapy of Pancreatic Ductal Adenocarcinoma","volume":"6","author":"Bailey","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in Cancer Immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial Sequencing and Analysis of the Human Genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The Sequence of the Human Genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10434-999-0046-z","article-title":"Current Advances and Changes in Treatment Strategy May Improve Survival and Quality of Life in Patients with Potentially Curable Gastric Cancer","volume":"6","author":"Roukos","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF02574474","article-title":"Role of Surgery in the Prophylaxis of Hereditary Cancer Syndromes","volume":"9","author":"Roukos","year":"2002","journal-title":"Ann. Surg. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/bmm.10.70","article-title":"Next-Generation, Genome Sequencing-Based Biomarkers: Concerns and Challenges for Medical Practice","volume":"4","author":"Roukos","year":"2010","journal-title":"Biomark. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra1204892","article-title":"The Implications of Clonal Genome Evolution for Cancer Medicine","volume":"368","author":"Aparicio","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature24286","article-title":"DNA Sequencing at 40: Past, Present and Future","volume":"550","author":"Shendure","year":"2017","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.drudis.2017.03.014","article-title":"Spatiotemporal Diversification of Intrapatient Genomic Clones and Early Drug Development Concepts Realize the Roadmap of Precision Cancer Medicine","volume":"22","author":"Roukos","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12943-023-01870-3","article-title":"Liquid Biopsy Techniques and Pancreatic Cancer: Diagnosis, Monitoring, and Evaluation","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"100116","DOI":"10.1016\/j.soi.2024.100116","article-title":"Utility of Tumor-Informed Circulating Tumor DNA for Detection of Minimal Residual Disease after Curative-Intent Therapy in Localized Pancreatic Cancer","volume":"2","author":"Dickey","year":"2025","journal-title":"Surg. Oncol. Insight"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating Tumor DNA as a Potential Marker of Adjuvant Chemotherapy Benefit Following Surgery for Localized Pancreatic Cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-021-10985-0","article-title":"Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy","volume":"29","author":"Kitahata","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","article-title":"Association of Personalized and Tumor-Informed ctDNA with Patient Survival Outcomes in Pancreatic Adenocarcinoma","volume":"29","author":"Botta","year":"2024","journal-title":"Oncologist"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jhbp.1282","article-title":"Prognostic Impact of Postoperative Circulating Tumor DNA as a Molecular Minimal Residual Disease Marker in Patients with Pancreatic Cancer Undergoing Surgical Resection","volume":"30","author":"Hata","year":"2023","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Jiang, J., Ye, S., Xu, Y., Chang, L., Hu, X., Ru, G., Guo, Y., Yi, X., Yang, L., and Huang, D. (2020). Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01220"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1245\/s10434-020-09278-9","article-title":"Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma","volume":"28","author":"Yamaguchi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/clinchem\/hvac153","article-title":"Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study","volume":"68","author":"Lee","year":"2022","journal-title":"Clin. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/1878-0261.70116","article-title":"Tumor-Agnostic Detection of Circulating Tumor DNA in Patients with Advanced Pancreatic Cancer Using Targeted DNA Methylation Sequencing and Cell-Free DNA Fragmentomics","volume":"19","author":"Lapin","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_147","unstructured":"U.S. Food and Drug Administration (2026). List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A Nationwide Comprehensive Genomic Profiling and Molecular Tumor Board Platform for Patients with Advanced Cancer","volume":"9","author":"Volders","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_149","first-page":"OP2500548","article-title":"Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients with Localized Pancreatic Ductal Adenocarcinoma","volume":"22","author":"Agritelley","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental Regulation of Tumor Progression and Metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The Clinical Role of the TME in Solid Cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14737159.8.1.29","article-title":"Innovative Genomic-Based Model for Personalized Treatment of Gastric Cancer: Integrating Current Standards and New Technologies","volume":"8","author":"Roukos","year":"2008","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Pan, D., Li, X., Qiao, X., and Wang, Q. (2025). Immunosuppressive Tumor Microenvironment in Pancreatic Cancer: Mechanisms and Therapeutic Targets. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1582305"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning Cold into Hot: Emerging Strategies to Fire up the Tumor Microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The Influence of Subclonal Resistance Mutations on Targeted Cancer Therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41586-024-08087-4","article-title":"Tumour Evolution and Microenvironment Interactions in 2D and 3D Space","volume":"634","author":"Mo","year":"2024","journal-title":"Nature"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Chen, K., Chen, Z., Wang, J., Zhou, M., Liu, Y., Xu, B., Yu, Z., Li, Y., Yang, G., and Xu, T. (2025). Single-Cell Sequencing Unravels Pancreatic Cancer: Novel Technologies Reveal Novel Aspects of Cellular Heterogeneity and Inform Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13123024"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"101894","DOI":"10.1016\/j.ctrv.2019.101894","article-title":"Comprehensive Intra-Individual Genomic and Transcriptional Heterogeneity: Evidence-Based Colorectal Cancer Precision Medicine","volume":"80","author":"Kyrochristos","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/wsbm.1254","article-title":"Genome Network Medicine: Innovation to Overcome Huge Challenges in Cancer Therapy","volume":"6","author":"Roukos","year":"2014","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41571-020-00449-x","article-title":"Applying High-Dimensional Single-Cell Technologies to the Analysis of Cancer Immunotherapy","volume":"18","author":"Gohil","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41586-025-08584-0","article-title":"Mass-Spectrometry-Based Proteomics: From Single Cells to Clinical Applications","volume":"638","author":"Guo","year":"2025","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"(2021). Method of the Year 2020: Spatially Resolved Transcriptomics. Nat. Methods, 18, 1.","DOI":"10.1038\/s41592-020-01033-y"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"(2024). Method of the Year 2024: Spatial Proteomics. Nat. Methods, 21, 2195\u20132196.","DOI":"10.1038\/s41592-024-02565-3"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing Anti-Tumour Efficacy with Immunotherapy Combinations","volume":"397","author":"Larkin","year":"2021","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent Drug Action in Combination Therapy: Implications for Precision Oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Hartupee, C., Nagalo, B.M., Chabu, C.Y., Tesfay, M.Z., Coleman-Barnett, J., West, J.T., and Moaven, O. (2024). Pancreatic Cancer Tumor Microenvironment Is a Major Therapeutic Barrier and Target. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1287459"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA Neoantigen Vaccines Prime Long-Lived CD8+ T Cells in Pancreatic Cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Yin, H., Zhang, Y., Zhang, J., and Dong, Q. (2025). Domestication and Feedback: Bidirectional Hijacking in Pancreatic Ductal Adenocarcinoma Microenvironment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1585858"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41592-024-02542-w","article-title":"Revolutionizing Cancer Research with Spatial Proteomics and Visual Intelligence","volume":"21","author":"Quail","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","article-title":"Macrophages and Fibroblasts as Regulators of the Immune Response in Pancreatic Cancer","volume":"26","author":"Shakiba","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and Specificities of T Cells in Cancer Immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ccell.2024.09.001","article-title":"Spatial Oncology: Translating Contextual Biology to the Clinic","volume":"42","author":"Gong","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1186\/s12967-025-07390-6","article-title":"Spatial Omics in 3D Culture Model Systems: Decoding Cellular Positioning Mechanisms and Microenvironmental Dynamics","volume":"23","author":"Du","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"101261","DOI":"10.1016\/j.cels.2025.101261","article-title":"Combining Spatial Transcriptomics and ECM Imaging in 3D for Mapping Cellular Interactions in the Tumor Microenvironment","volume":"16","author":"Pentimalli","year":"2025","journal-title":"Cell Syst."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Larson, C.R., Mandloi, A., Acharyya, S., and Carstens, J.L. (2025). The Tumor Microenvironment across Four Dimensions: Assessing Space and Time in Cancer Biology. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1554114"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.annonc.2023.09.2960","article-title":"237TiP GUIDE.MRD: A Consortium Guiding Multi-Modal Therapies against Minimal Residual Disease (MRD) by Liquid Biopsy to Assess Implementation of Circulating Tumor DNA (ctDNA) in Clinical Practice to Improve Patient Outcomes","volume":"34","author":"Pantel","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:33:44Z","timestamp":1780720424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":177,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111824"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111824","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}